Oncology - Renal/Urologic News & Articles

521 PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality Molecular Cancer Research, March 20, 2013    Clinical Article

522 Dihydrotestosterone and Bicalutamide Do Not Affect Periostin Expression in Androgen-dependent LNCaP Prostate Cancer Cell Lines Anticancer Research, March 20, 2013    Clinical Article

523 YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α Cancer Immunology, Immunotherapy, March 20, 2013    Clinical Article

524 Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413 Cancer, March 20, 2013    Clinical Article

525 Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer Urologic Oncology: Seminars and Original Investigations, March 20, 2013    Review Article    Clinical Article

526 Serum levels of 17-β-estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort Urologic Oncology: Seminars and Original Investigations, March 20, 2013    Clinical Article

527 Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urologic Oncology: Seminars and Original Investigations, March 20, 2013    Clinical Article

528 Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma Modern Pathology, March 20, 2013    Clinical Article

529 A case-control study on the association between bladder cancer and prior bladder calculus Full Text BMC Cancer, March 20, 2013    Clinical Article

530 Risk of prostate cancer death in long-term users of warfarin: a population-based case-control study Cancer Causes and Control, March 19, 2013    Clinical Article

531 Tumor suppressor miRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue Cancer Prevention Research, March 19, 2013    Clinical Article

532 HOXB13: A High-Penetrance Prostate Cancer Gene Cancer Epidemiology, Biomarkers & Prevention, March 19, 2013    Clinical Article

533 miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis British Journal of Cancer, March 19, 2013    Clinical Article

534 Hsp27 regulates epithelial mesenchymal transition, metastasis and circulating tumor cells in prostate cancer Cancer Research, March 19, 2013    Clinical Article

535 Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome) BJU International, March 19, 2013    Clinical Article

536 A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years BJU International, March 19, 2013    Clinical Article

537 Piper betel leaf extract: anticancer benefits and bio-guided fractionation to identify active principles for prostate cancer management Carcinogenesis, March 19, 2013    Clinical Article

538 Patterns of renal angiomyolipoma regression post embolisation on medium- to long-term follow-up British Journal of Radiology, March 19, 2013

539 Bilateral Wilms tumour in a developing country: a descriptive study Pediatric Surgery International, March 19, 2013    Review Article

540 Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer ells Endocrine-Related Cancer, March 19, 2013    Review Article

1 Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Annals of Oncology, April 19, 2013

2 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013

3 Gene-Environment Interactions in Bladder Cancer Cancer Research, April 1, 2013

4 Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer Annual Review of Medicine, April 26, 2013    Review Article

5 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013

6 The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies World Journal of Urology, April 2, 2013    Review Article

7 Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer Current Opinion in Oncology, April 10, 2013    Review Article

8 Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma Urologic Oncology: Seminars and Original Investigations, April 1, 2013

9 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, April 24, 2013

10 Advances in bladder cancer imaging BMC Medicine, April 15, 2013    Free full text    Review Article

11 Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer Cancer Causes and Control, April 8, 2013

12 Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort European Journal of Cancer, March 22, 2013

13 Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer Journal of the National Cancer Institute, April 11, 2013

14 Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria British Journal of Haematology, April 26, 2013

15 Low serum testosterone levels are predictive of prostate cancer World Journal of Urology, April 9, 2013

16 Aberrant BAF57 Signaling Facilitates Pro-metastatic Phenotypes Clinical Cancer Research, April 1, 2013

17 Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology, March 25, 2013

18 Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09) The Lancet Oncology, March 7, 2013

19 Urothelial carcinoma of the bladder and the upper tract: disparate twins The Journal of Urology, April 18, 2013    Review Article

20 A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Annals of Oncology, April 19, 2013